Invest Like the Richest People on the Planet

It’s no secret that the wealthiest one percent on this planet don’t buy and sell stocks all day.

They don’t have to, because they are gifted the opportunity to invest in companies before they go public. And when they go public, they cash out for more money than most folks will make in their entire lifetimes.

Just think about the early investors in Google, Facebook, and Tesla.

Folks who had the opportunity to buy in before those companies went public are now some of the richest people on the planet.

• Andy Bechtolsheim: Invested $100k in Google before it went pubic — made $1.5 billion
• David Choe: Got $60k in Facebook stock before it went public — made $2 million
• Nancy Pfund: Got in on Tesla before it went public — now runs a $400 million VC fund

Of course, you never had the opportunity to get in on these early deals because you simply had no way to know about them. There was no one around to tip you off to these deals. Until now…

The Lucky Ones

Last week, I had the opportunity to take part in a capital raise for a Canada-based cannabis company that would allow me to double my money in about five months and triple my money in less than a year.

This deal was only for accredited investors, and it had only been shared with a small group of people.

I was one of the lucky ones.

You see, here in our Baltimore office, I sit directly behind our resident “green guru,” Jeff Siegel.

If you’re unfamiliar with Jeff, he was one of the first to recommend Tesla (NADSAQ: TSLA), back when hardly any analyst would touch the company. Here’s how that worked out for him…

Now, a few weeks ago, I overheard Jeff on the phone talking about this new deal he just found… a deal that would basically allow him to get shares of a company — at a tremendous discount — before it was set to go public.

Clearly I wanted a piece of that action, and Jeff was more than happy to let me dip my beak.

Want in?

Now, I won’t make any apologies for leveraging my connections to take advantage of this deal. After all, I’m here to make money just like you. And if this is Jeff’s “next Tesla,” I want in!

Of course, the truth is, Jeff usually keeps these types of things under the radar (sharing only with colleagues and his small private investment group). But later this week, I’m going to be able to get you in on some of these deals, too.

You see, Jeff runs a small investment group where he, along with other members, shares his latest investment strategies. Most of these strategies revolve around getting in on early-stage private deals not available to “regular investors.”

Last week, I told Jeff that he should consider inviting you to take part in some of these deals, too. After all, it had recently come to my attention that there were a few open spots available for this exclusive investment group. It’s limited to just 500 people.

He resisted at first, but after a few drinks and a reminder that he still owed me one for tipping him off to a very lucrative lithium deal last year, he agreed.

Now, Jeff is putting the finishing touches on his next private deal. If you want a piece of it, you’ll have to fill out a membership application first. So I’ll send that over to you tomorrow.

Until next time,

Keith Kohl

Check us out on YouTube!

A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.

For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.

Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.